Molecular targeted therapy in malignant melanoma
10.3760/cma.j.issn.1673-422X.2018.11.014
- VernacularTitle:分子靶向治疗在恶性黑色素瘤中的应用
- Author:
Qiuju MIAO
1
;
Yifei WANG
;
Xiulian XU
Author Information
1. 中国医学科学院皮肤病医院病理科
- Keywords:
Melanoma;
Drug therapy;
Enzyme inhibitors;
Drug resistance
- From:
Journal of International Oncology
2018;45(11):699-702
- CountryChina
- Language:Chinese
-
Abstract:
Malignant melanoma is the most common fatal skin tumor.Molecular targeted drugs effect on advanced and metastatic melanoma is remarkable,including mitogen-activated protein kinase (MAPK) inhibitors,phosphatidylinositide 3-kinase (PI3K) inhibitors,receptor tyrosine kinase (TKR) inhibitors and vascular endothelial growth factor (VEGF) inhibitors.Vemurafenib and Dabrafenib,as the representative of the v-Raf murine sarcoma viral oncogene homolog B1 (BARF) kinase inhibitors,play important roles for malignant melanoma.However,the primary or acquired drug resistance to this drug limits its clinical use.At present,some new molecular targeted drugs such as Trametinib,representative of mitogen-activated extracellular signalregulated kinase (MEK) inhibitors,have been used and patients can benefit from the treatment.Studies on the mechanism of drug resistance and the combination of multiple target drugs also provide more potential for individualized molecular targeted therapy of malignant melanoma.
